What to Expect From Edwards Lifesciences' Q4 2025 Earnings Report

Core Insights - Edwards Lifesciences Corporation (EW) is valued at a market cap of $48.2 billion and specializes in medical technology for serious heart conditions [1] Financial Performance - Analysts expect EW to report a profit of $0.61 per share for fiscal Q4 2025, reflecting a 3.4% increase from $0.59 per share in the same quarter last year [2] - For the current fiscal year ending in December, EW is projected to report a profit of $2.59 per share, up 6.6% from $2.43 per share in fiscal 2024, with further growth expected to $2.90 in fiscal 2026 [3] Stock Performance - EW's stock has gained 13.1% over the past 52 weeks, underperforming the S&P 500 Index's 19.7% return but outperforming the State Street Health Care Select Sector SPDR ETF's 12.7% increase [4] - Following the Q3 results announcement, EW's shares fell by 1.2% in the subsequent trading session despite a 14.7% year-over-year increase in net sales to $1.6 billion [5] Analyst Ratings - Wall Street analysts have a "Moderate Buy" rating on EW, with 18 out of 31 analysts recommending "Strong Buy," 2 suggesting "Moderate Buy," and 11 indicating "Hold" [6] - The mean price target for EW is $96.32, suggesting a 16% potential upside from current levels [6]